Skip to main content
eScholarship
Open Access Publications from the University of California

Proceedings of UCLA Health

Proceedings of UCLA Health bannerUCLA

Toxicity of Bevacizumab (bev): The First in Class Anti-Angiogenesis Agent in Oncology

Main Content
For improved accessibility of PDF content, download the file to your device.
Current View